By decreasing transforming growth factor β1 (TGF-β1) and IL-10, artesunate reversed the immunosuppression from Colon26 and RKO colorectal cancer cells (23), while it exerted an anti-immunosuppressive effect on cervical cancer by repressing PGE2 production and Foxp3 expression, making it a promising drug for immunotherapy of cervical cancer (13). Here, TGFB1 is linked to cervical carcinoma.